Skip to content
DataLookout
Menu

NCT04843098

Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Phase changed: Phase 1/2 → Phase 1 Show 4 more changesShow less
    • Eligibility criteria expanded, about 23 words
    • Trial completed
    • Final enrollment: 13 participants (planned 108)
    • Study completion date changed from estimate of Jun 2025 to Apr 23, 2025
  2. Notable Primary completion date changed from estimate of Jan 2024 to Nov 20, 2024v2 Show 4 more changesShow less
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study sites: 0 to 1
    • Study completion date: Jan 2024 to Jun 2025
    • Start date changed from estimate of Apr 2021 to May 26, 2021
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Phase Ia -Dose Limiting Toxicity (DLT) of TL117 treatment
Timeframe: From time of the first dosing to time of Cycle 1 Day 28(each cycle is 28 days)
Phase Ib -Dose Limiting Toxicity (DLT) of TL117 plus paclitaxel combination treatment
Timeframe: From time of the first dosing to time of Cycle 1 Day 28(each cycle is 28 days)
Phase II - Objective response rate (ORR)
Timeframe: Every 8 weeks from date of first treatment until date of last treatment up to 12 months

Arms and interventions

Single arm, open labelExperimental

Phase 1a: All subjects receiving TL117 alone (20-120 mg); Phase 1b: All subjects receiving TL117 (MTD-1 or MTD) plus Paclitaxel; Phase 2: All subjects receiving TL117 in combination with Paclitaxel at RP2D

Drugs: TL117, Paclitaxel

Sites

1 site in 1 country

  • Shanghai East HospitalShanghai, Shanghai Municipality, China